Rallybio Further Expands Drug Acquisition and Development Capabilities Rallybio Welcomes Laura Ekas, PhD and Eric Watsky, MD, Further Expanding Rallybio’s Drug Acquisition and Development Capabilities FARMINGTON, Connecticut, August 7, 2018 – Rallybio LLC, a...
Harpoon Therapeutics treats first patient with HPN424 in phase I clinical trial of metastatic castration-resistant prostate cancer (mCRPC) patients. HPN424, First-in-Class TriTAC™ T Cell Redirection Therapy, Targets Prostate-Specific Membrane Antigen (PSMA) Clinical...
ReViral announces Series B investment ReViral announces US$55 million series B fundraising to advance RSV clinical studies London, UK – 1st August 2018: ReViral, an antiviral drug discovery and development company, focused on diseases caused by the Respiratory...
Neuronetics, Inc., Maker of NeuroStar® Advanced Therapy, Announces Pricing of Initial Public Offering MALVERN, Pa., June 28, 2018 (GLOBE NEWSWIRE) — Neuronetics, Inc., a commercial-stage medical device company focused on designing, developing, and manufacturing...
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock WALTHAM, Mass.–(BUSINESS WIRE)–Jun. 11, 2018– Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key...
Iterum Therapeutics Announces Pricing of Initial Public Offering DUBLIN and CHICAGO, May 24, 2018 /PRNewswire/ — Iterum Therapeutics plc (NASDAQ:ITRM), a clinical-stage pharmaceutical company developing anti-infectives aimed at combatting the global crisis of...
Recent Comments